ERBB2 and neoplasm: Chia-Yu Su reported a tumor inhibitory rate of 88.9% for HER2-LsbMDDs (bispecific antibody conjugated drug-loaded lecithin-stabilized micellar drug delivery system), exceeding all comparators (85.8–80.1%) [80].